Priority Lists
Protocol Posting of
Activations
A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) In Patients with Malignant Pleural Mesothelioma
| Study Coordinator(s) | Linda L. Garland, M.D., Michael Lobell, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Closures
Correlation of DNA Damage Index and Clinical Response in the Context of ECOG Trial E3695: A Randomized Phase III Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Dacarbazine, IL-2 and Interferon Alfa-2b Versus Cisplatin, Vinblastine, Dacarbazine Alone in Patients with Metastatic Malignant Melanoma
| Study Coordinator(s) | Jeffrey A. Sosman, M.D. |
| Participants | Members, NCORP |
| Closure Date | 2002-04-18 |
A Randomized Phase III Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Dacarbazine, IL-2 and Interferon a-2b versus Cisplatin, Vinblastine, Dacarbazine Alone in Patients with Metastatic Malignant Melanoma
| Study Coordinator(s) | Lawrence E. Flaherty, M.D. |
| Participants | Medical Oncologists, NCORP, Members |
| Closure Date | 2002-04-17 |
Partial Closure Arm A Effective 4/23/02
A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU) and Irinotecan (CPT-11) as Initial Treatment of Patients With Advanced Adenocarcinoma of the Colon and Rectum
| Study Coordinator(s) | Stephen K. Williamson, M.D. |
| Participants | Members, Surgeons, NCORP |
| Closure Date | 2002-07-18 |
Amendments, Revisions, Memoranda
Revision #5
A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen
| Study Coordinator(s) | Silvana Martino, D.O. |
Revision #7
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Overexpressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer
| Study Coordinator(s) | Silvana Martino, D.O. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Surgeons |
Memorandum
A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Colorectal Cancer.
| Study Coordinator(s) | Robert P. Whitehead, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Memorandum
A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Pancreas Cancer.
| Study Coordinator(s) | John S. Macdonald, M.D., Robert P. Whitehead, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Revision #11
Postoperative Evaluation of 5-FU by Bolus Injection versus 5-FU by Prolonged Venous Infusion Prior to and Following Combined Prolonged Venous Infusion Plus Pelvic XRT Versus Bolus 5-FU Plus Leucovorin Plus Levamisole Prior to and Following Combined Pelvic XRT in Patients with Rectal Cancer, Phase III, Intergroup
| Study Coordinator(s) | Stephen R. Smalley, M.D., Stephen K. Williamson, M.D., Norman C. Estes, M.D., John M. Robertson, M.D. |
| Participants | Members, Radiation Oncologists, Surgeons, Pathologists, CALGB, ECOG, NCCTG, RTOG, NCIC-CTG, NCORP |
Revision #8
Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma, A BMT Study, Phase III
| Study Coordinator(s) | Alexander Fefer, M.D., John A. Thompson, M.D., Patricia K. Lillis-Hearne, M.D. |
| Participants | Limited Institutions: BMT Members |
Revision #3
Gastrointestinal Tumor Repository Protocol, Ancillary
| Study Coordinator(s) | Cecilia M. Fenoglio-Preiser, M.D., Grant N. Stemmermann, M.D., Amy E. Noffsinger, M.D., Paul E. Hurtubise, M.D. |
| Participants | Members, Pathologists, NCORP |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required